Special Issue "Immune Mediated Inflammatory Diseases: From an Update on Molecular and Cellular Mechanisms to Biomarkers for Personalized Medicine"
A special issue of Biomedicines (ISSN 2227-9059).
Deadline for manuscript submissions: 30 June 2020.
Interests: arthritis; T-cells; Treg; Th17; inflammation; IL6; IL7; epigenetics
IMIDs are common conditions which cause pain, distress and loss of function, characterised by a burden of inflammatory leading to organ damage and increased morbidity and/or mortality. Inflammation may result from or be caused by an inadequate immune response for which an autoantigen has been identified in some conditions. An underlying manifestation of this shared immune dysregulation in clinically unrelated conditions is the inappropriate activation of inflammatory cytokines, notably, IL6 or TNF-alpha.
Although treatment of IMIDs has been revolutionised by the use of targeted biologic therapies with good efficacy, speed of onset and tolerability (such as cytokines blockade initially), response to therapies remains heterogeneous between patients, while the development of resistance to treatments over time is also a reason for inadequate response. This, nonetheless, has led to a shift in the management of these conditions from an organ‐based symptom relief approach to a disease mechanism modification-based treatment. As a result, tailored approaches are now possible and recognised as a high research priority in order to give the right drug to the right patient at the right time.
The Special Issue “Immune Mediated Inflammatory Diseases: From an Update on Molecular and Cellular Mechanisms to Biomarkers for Personalized Medicine” is related to new insight into the mechanism of in IMIDs from molecular and cellular events leading to the establishment of chronicity in these diseases, from epigenetics, gene expression, phenotyping or functional work, cytokine/chemokines networking ….etc. Research into biomarker for diagnostic, prognostic and prediction of response to treatment / relapse, are also invited from any stage of development from discovery to validation/replication studies. Both original research and comprehensive review are welcomed.
Prof. Frédérique Ponchel
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- molecular pathways
- cellular immune mechanisms
- cyokine/chemokine networks
- diagnostic, prognostic
- response to therapy